Edition:
India

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

57.40USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$57.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
165,605
52-wk High
$66.55
52-wk Low
$38.15

Select another date:

Tue, Jan 2 2018

BRIEF-Aerie Pharmaceuticals Appoints Julia Williams As Director Of Medical Affairs

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF JULIA WILLIAMS AS DIRECTOR OF MEDICAL AFFAIRS Source text for Eikon: Further company coverage:

BRIEF-Aerie Pharma Enters Controlled Equity Offering Sales Agreement With Cantor Fitzgerald

* AERIE PHARMA SAYS ON DEC 19, CO ENTERED INTO CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD - SEC FILING

Aerie's glaucoma treatment gets early FDA approval

Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.

UPDATE 2-Aerie's glaucoma treatment gets early FDA approval

Dec 18 Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.

Aerie's glaucoma treatment gets early FDA approval

Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.

BRIEF-Aerie Pharmaceuticals Gets U.S. FDA Approval Of Glaucoma Drug

* AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE LOWERING OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

FDA approves Aerie's glaucoma treatment

Dec 18 Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its treatment for glaucoma, Rhopressa.

BRIEF-Aerie Pharmaceuticals Appoints Heather Johnson As Regional Sales Director For Northeast Region

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF HEATHER JOHNSON AS REGIONAL SALES DIRECTOR FOR THE NORTHEAST REGION Source text for Eikon: Further company coverage:

BRIEF-Aerie Pharmaceuticals announces appointment Of Nhi Ong director of analytics

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF NHI ONG AS DIRECTOR OF ANALYTICS Source text for Eikon: Further company coverage:

BRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial

* Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan

Select another date: